Exhibitor Product Theater

What’s Possible With Tremfya®? Exploring Long-Term Outcomes in Crohn’s Disease and Ulcerative Colitis

Tauseef Ali, MD, FACG, Jessica R. Allegretti, MD, MPH, FACG
10:35 am – 11:30 am

Join experts Dr. Tauseef Ali and Dr. Jessica Allegretti as they explore long-term data with Tremfya® for the treatment of moderately to severely active Crohn’s Disease and Ulcerative Colitis. This session will highlight efficacy and safety outcomes, deep remission findings across patient populations, and share perspectives on patient care in today's increasingly complex IBD treatment landscape.

This program is sponsored by Johnson and Johnson.

Evolving Infliximab Maintenance: Insights from Emerging Post-hoc and Real-World Evidence of ZYMFENTRA® (infliximab-dyyb)

Aja S. McCutchen, MD
11:45 am – 12:15 pm

This program will highlight the growing evidence supporting subcutaneous infliximab maintenance, spanning the LIBERTY registration and extension studies. Discussion will include longterm efficacy and durability outcomes, clinically relevant subgroup analyses, and real-world evidence from Europe evaluating IV-to-SC transition.

This event is sponsored by Celltrion Inc.

Reach for Treatment Goals Together

Erica R. Cohen, MD, FACG, Amy L. Stewart, FNP-C
12:30 pm – 1:00 pm

Discuss short-, intermediate-, and long-term treatment goals for adult patients with moderately to severely active ulcerative colitis or Crohn’s disease. Also review bowel urgency data, long-term data, including efficacy regardless of biologic experience, and access & patient support services for a treatment option.

This program is sponsored by Eli Lilly and Company.

Low-Risk on Histology. High-Risk in Reality: Johnny Walker's Journey with Barrett's Esophagus

Mark S. Amorosino, MD, David G. Forcione, MD, FACG, Johnny Walker
1:15 pm – 1:45 pm

Come hear Johnny Walker share the story of his unexpected diagnosis of non-dysplastic Barrett's esophagus and how TissueCypher risk stratification helped his gastroenterologist, Dr. Mark Amorosino, identify hidden progression risk. This led to a referral to interventional gastroenterologist Dr. David Forcione, who discovered progression as ablative therapy was initiated. All three will be present for questions during this panel discussion.

This program is sponsored by Castle Biosciences.

The Pancreas, the Bile Duct, and Beyond: Exploring a Treatment Option for IgG4-Related Disease

Bradford J. Chong, MD
2:00 pm – 2:30 pm

Highlight expert perspectives on diagnosing IgG4-RD and its manifestations, including type 1 AIP and IgG4-related sclerosing cholangitis. Review the importance of assessing patients with IgG4- RD for extra-GI manifestations and highlight clinical trial data.

This program is sponsored by Amgen Inc.

A New Era in EoE: Exploring Epithelial-Driven Inflammation From the Top of the Cytokine Cascade

Nirmala Gonzalves, MD, Evan Dellon, MD, MPH, FACG
2:45 pm – 3:15 pm

Management of EoE is evolving—and so is our understanding of what drives it. Join Amgen and AstraZeneca for a dynamic, expert‑led symposium that takes a fresh look at EoE through the lens of inflammation driven by the mucosal epithelium. Starting at the top of the inflammatory cascade, this session connects cutting‑edge science with clinical reality, offering insights into disease initiation, progression, and impact. If you manage EoE, this is a conversation you won’t want to miss.

This program is sponsored by Amgen and AstraZeneca.

Clinical Insights Into a First-in-Class Treatment for Primary Biliary Cholangitis (PBC)

Marcelo Kugelmas, MD
3:30 pm – 4:00 pm

Join us for a product theater on an FDA-approved treatment option for primary biliary cholangitis (PBC). Gain insights into how this therapy may support improved PBC outcomes for the appropriate patients affected by this chronic liver disease.

This program is sponsored by Gilead Sciences Inc.